Article

Hemodynamic effects of calcium channel blockers at rest and during exercise in essential hypertension.

The American Journal of Medicine (Impact Factor: 5.3). 11/1985; 79(4A):11-8. DOI: 10.1016/0002-9343(85)90495-4
Source: PubMed

ABSTRACT The main hemodynamic disturbance occurring in patients with essential hypertension is an increase in the total peripheral resistance. In young patients with hypertension, this disturbance is clearly seen during muscular exercise, even though the calculated resistance might be normal during rest. This article reports results of studies on the long-term hemodynamic effects of two calcium channel blockers, verapamil and nifedipine, in patients with mild to moderate hypertension. Twenty-five men, aged 20 to 64 years, with diastolic blood pressures between 100 and 120 mm Hg before treatment were studied at rest and during exercise on ergometer bicycles. Blood pressure was recorded intra-arterially, and cardiac output was measured. After this initial study, 10 patients were treated with verapamil (from 40 to 80 mg, three times daily) and 15 patients with nifedipine (long-acting form, from 40 to 80 mg daily). After one year, the hemodynamic study was repeated. Both drugs induced a reduction in blood pressure and in the total peripheral resistance without any reduction in the cardiac index. Verapamil reduced heart rate, particularly during exercise, but this effect was compensated by an increase in the stroke volume. The hemodynamic profile of these two calcium channel blockers clearly differs from the hemodynamic effects of beta blockers.

0 Bookmarks
 · 
17 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To clarify the hemodynamic effects of verapamil, we investigated in normal volunteers the effects of 4-day treatment with verapamil (240 mg/day) on left ventricular function and on systemic and brachial artery haemodynamics, in comparison with the effects of placebo and atenolol (100 mg/day). Left ventricular structure and function was evaluated by echocardiography, systemic hemodynamics were assessed by pulsed Doppler velocimetry of the ascending aorta, and brachial artery hemodynamics were assessed pulsed Doppler velocimetry of the brachial artery. Verapamil decreased systemic and brachial artery vascular resistance (p less than 0.05), increased cardiac output (CO, p less than 0.01) and brachial flow (p = 0.054), and did not affect blood pressure (BP) and heart rate (HR). In contrast, atenolol decreased BP, HR, and CO (p less than 0.001) but did not significantly affect brachial flow and systemic and brachial artery vascular resistance. We conclude that short-term administration of verapamil in normal humans produces systemic and brachial artery vasodilatation, with a reflex increase of stroke volume but not of HR.
    Journal of Cardiovascular Pharmacology 11/1989; 14(4):642-7. · 2.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of verapamil (240 mg) on exercise capacity was studied during a short graded and a single-level endurance exercise test in 12 normal volunteers; it was compared to the effects of atenolol (100 mg x day-1). Intake of verapamil, atenolol and placebo, administered according to a randomized, double-blind cross-over design, was started 3 days before the exercise tests. Compared to placebo, verapamil did not affect peak oxygen uptake in the graded test or exercise duration in the endurance test. Heart rate, systolic blood pressure, rating of perceived exertion and respiratory data at submaximal and peak exercise were unaffected in either test. On the other hand atenolol reduced maximal oxygen uptake by 5% (p less than 0.001) and endurance exercise duration by 17% (p less than 0.05). Besides marked decreases in heart rate and systolic blood pressure during the two types of exercise, atenolol also reduced oxygen uptake at submaximal exercise levels and it increased the rating of perceived exertion (p less than 0.05), the latter only during the endurance exercise test.
    European Journal of Applied Physiology and Occupational Physiology 02/1988; 58(1-2):87-91.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of felodipine, a new calcium antagonist, as monotherapy in mild and moderate hypertension (supine diastolic blood pressure between 95 and 100mm Hg: phase V) was investigated in a placebo-controlled, double-blind study of 109 patients from 13 centres using 3 different doses. After a 2-week placebo run-in phase the patients were randomised in a double-blind fashion to receive felodipine 2.5mg bid (32 patients), 5mg bid (30 patients), 10mg bid (24 patients) or placebo (25 patients). Clinical and laboratory measurements were performed after 1, 3 and 8 weeks. 94 patients completed the study. Felodipine reduced supine systolic blood pressure by 22mm Hg from baseline after 8 weeks’ treatment on 2.5mg bid, 24mm Hg on 5mg bid and 24mm Hg on 10mg bid at 2 hours after dosage. The corresponding reduction in the placebo group was 6mm Hg. There was a reduction in supine diastolic blood pressure from baseline of 13mm Hg on felodipine 2.5mg bid, 14mm Hg on felodipine 5mg bid and 20mm Hg on felodipine 10mg bid, with no reduction in patients receiving placebo. The percentage of patients completing the study who achieved a supine diastolic blood pressure of 90mm Hg or less after 8 weeks’ treatment at 2 hours after dosage was 9% on placebo, 67% on felodipine 2.5mg bid, 57% on felodipine 5mg bid and 92% on felodipine 10mg bid; and at 12 hours after dosage those achieving target supine diastolic blood pressure was 17% on placebo, 37% on felodipine 2 5mg bid, 25% on felodipine 5mg bid and 62% on felodipine 10mg bid. Felodipine was generally well tolerated, although 10 patients on felodipine 10mg bid (42%), 1 on felodipine 5mg bid (3%) and 2 on felodipine 2.5mg bid (6%) withdrew from the study because of adverse effects. One serious adverse event, a myocardial infarction, occurred during the study in a patient with a history of postprandial non-exertional chest pain. In conclusion, felodipine monotherapy appreciably reduces blood pressure in mild and moderate hypertension without significant tachycardia in the short term. Doses of felodipine 2.5mg bid and 5mg bid are better tolerated than 10mg bid and can be recommended for initial treatment in this category of patients.
    Drugs 12/1987; 34(3). · 4.13 Impact Factor